Cytopenia

01/01/2022 - "Since rituximab is effective in depletion of B cells and management of refractory immune-mediated cytopenia following HCT, we have added rituximab to the conditioning regimen. "
07/01/2007 - "We conclude that rituximab is an effective treatment for autoimmune cytopenias in children with immune deficiencies, but repeated courses of treatment may be needed."
01/01/2016 - "Additionally, rituximab has been used safely to treat autoimmune cytopenias in patients with CVID5. "
06/01/2013 - "This study examined the efficacy of rituximab in children with refractory autoimmune cytopenia. "
01/01/2023 - "This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed. "

01/01/2023 - "Steroid treatment improved cytopenia in about half of patients, with 26% achieving a complete recovery lasting for a median of 12 months. "
02/01/2021 - "Nine (75%) cytopenias responded to intravenous steroids. "
05/01/2006 - "All patients were off steroids or under low doses alternate day steroid medication when dysimmune cytopenia developed. "
07/01/2005 - "Adult patients with steroid refractory auto-immune cytopenias were included. "
05/01/2005 - "This preliminary experience suggests that MMF may spare steroid usage in patients with ALPS-associated cytopenias."

01/01/2017 - "In both cases, treatment with sirolimus was started, with a rapid response, complete remission of cytopenias, and resolution of lymphoproliferation, with no significant adverse effects. "
01/01/2020 - "In conclusion, sirolimus is effective for patients with primary relapsed/refractory autoimmune cytopenia with a low relapse rate and good tolerance."
01/01/2023 - "Recent studies found that sirolimus was effective in autoimmune cytopenia with a low relapse rate. "
01/07/2016 - "Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial."
01/01/2022 - "Rapamycin is effective in improving lymphoproliferation and cytopenia. "

01/01/2019 - "He was diagnosed with refractory cytopenia in childhood, but gradually improved after cyclosporine treatment. "
05/01/2022 - "The objective of this clinical case report is to highlight the possibly beneficial role of cyclosporine in controlling cytopenia in CID patients. "
05/01/2022 - "A rare case of combined immunodeficiency with cytopenia whose symptoms were controlled by cyclosporine."
01/01/2022 - "Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers."
05/14/2018 - "Treatment with cyclosporin in auto-immune cytopenias in children: The experience from the French cohort OBS'CEREVANCE."

05/01/2000 - "These cases illustrate that intravenous immunoglobulins may be helpful in refractory cases of autoimmune cytopenias. "
11/26/2023 - "Intravenous immunoglobulins in autoimmune cytopenias: an old tool with an alternative dosing schedule."
01/01/2021 - "All 5 patients tolerated myeloablative conditioning regimens and had robust donor cell engraftment with resolution of cytopenias and independence from intravenous immunoglobulin substitution. "
12/01/2018 - "Hepatocellular injury and hematologic cytopenia after high-dose intravenous immunoglobulin administration."
03/01/2013 - "Unlike many patients with idiopathic autoimmune cytopenias, the cytopenias in patients with ALPS typically do not respond to IVIg. "

01/01/2018 - "Although cytopenias were the most common adverse events associated with ruxolitinib treatment, a COMFORT-I analysis showed that they were managed effectively with dose modifications, without a negative impact on the efficacy of ruxolitinib. "
12/01/2016 - "Low-dose ruxolitinib at 5 mg/day was safe and effective, but one of two patients treated at 10 mg/day of ruxolitinib was complicated with severe cytopenia. "
05/01/2020 - "Future studies should identify patients less likely to respond to ruxolitinib and/or focus on a more targeted approaches to reduce infectious complications and cytopenias seen with this drug."
01/01/2023 - "After competing risk analysis, the cumulative incidence of ruxolitinib discontinuation at 5 years was 57% and 38% in patients with cytopenia and the proliferative phenotype (p < .001), whereas cumulative incidence of leukemic transformation was similar (p = .06). "
01/01/2023 - "Patients with cytopenia received lower average ruxolitinib at the starting (25.2 mg/day vs. 30.2 mg/day, p < .001) and overall doses (23.6 mg/day vs. 26.8 mg/day, p < .001) and achieved lower rates of spleen (26.5% vs. 34.1%, p = .04) and symptom (59.8% vs. 68.8%, p = .008) responses at 6 months compared with patients with the proliferative phenotype. "

08/15/2001 - "It was concluded that thalidomide, as a single agent, is effective in improving cytopenias of some MDS patients, especially those who present without excess blasts. "
02/25/2023 - "Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. "
05/01/2006 - "Nine patients (22%) had deterioration that was attributed to thalidomide (resolved after withdrawal) with either progressive cytopenias or excessive proliferation. "
02/01/2010 - "The high incidence of cytopenia in this study suggests that the Japanese population tends to display bone marrow suppression after thalidomide therapy. "
07/01/2004 - "Thalidomide-based therapy has the potential to produce durable responses in MMM-associated cytopenias, even after discontinuation of the drug."

04/01/2021 - "To investigate the factors affecting the chronicity of childhood primary immune thrombo-cytopenia (ITP) and compare the efficiency of different first-line treatment regimens. "
01/12/2023 - "We therefore theorized that a small molecule drug discovery-based approach to the treatment of immune cytopenias (ITP, AIHA, HTR, DHTR) is feasible. "
01/01/2021 - "We retrospectively collected 47 pediatric patients with at least one hematological disorder among which persistent/chronic ITP, AIHA, and AIN, aged 0-18 years at onset of immune cytopenias and/or immune-dysregulation. "
01/01/2019 - "On October 2016, eight patients (7/181 ES, 1/371 AIHA, and 0/615 ITP) were identified, all male, with a median age (range) at cytopenia onset of 11.5 years (1.6-15.8). "
01/01/2018 - "Methods We selected all newly diagnosed ITP adults included in the Cytopénies Auto-immunes Registre Midi-PyrénéEN (CARMEN) register and at the French referral center for autoimmune cytopenias. "

12/01/2019 - "Cytopenias improved in all patients within the first week of treatment, leading to relatively rapid transfusion independence, discontinuation of corticosteroids, and hospital discharge. "
03/01/1992 - "In all 3 cases the cytopenia improved following the initiation of treatment with systemic corticosteroids. "
07/01/2011 - "In patients with autoimmune cytopenia and CLL, treatment is as for idiopathic autoimmune cytopenia, with most patients responding to corticosteroids. "
02/01/2008 - "The major adverse events were thromboembolic events, corticosteroid-related morbidity, and cytopenias. "
01/01/2020 - "Cytopenia improved after 1 month of corticosteroid therapy. "

12/20/2008 - "We analyzed 362 low-risk, transfusion-dependent patients with MDS, with or without the del(5q) abnormality, enrolled in two phase II studies (MDS-003 and MDS-002) to determine whether treatment-related cytopenias are correlated with lenalidomide response. "
07/01/2022 - "They developed cytopenias while being on lenalidomide which was refractory to lenalidomide cessation, prompting bone marrow biopsy. "
11/01/2017 - "This case demonstrates how effective management of cytopenias, through dose interruptions and modifications in the early weeks of treatment, helps to enable long-term lenalidomide treatment and a high quality of life. "
07/11/2017 - "A man with cytopenias, dysplasia, excess blasts, P53 and RUNX1 mutations, and ring chromosome 7 recovered after stopping lenalidomide."
09/01/2014 - "The dose of lenalidomide was not escalated beyond 10 mg because of cytopenias requiring repeated dose delays and reductions. "

09/01/2001 - "This therapy was performed safely and he made a marked recovery from his cytopenia that had not been improved with any other therapy. "
07/01/2014 - "These therapies can be effective in the relief of cytopenias, achievement of cytogenetic remissions, and reduction in bone marrow blasts. "
01/01/2013 - "When standard therapies for ALPS-related cytopenias fail, clinicians are often forced to consider novel treatment options. "
12/01/2018 - "Additionally, beyond the possible harm and lack of efficacy of such therapies if the diagnosis of MDS is erroneous, the secondary myelodysplasia and resultant cytopenias are not likely to resolve unless the underlying etiology is identified and addressed. "
10/01/2018 - "Genetic characterization of chronic and refractory autoimmune cytopenias has led to targeted therapies with improved clinical outcomes and fewer off-target toxicities. "

12/01/2009 - "Both patients underwent uneventful splenectomy and experienced significant improvement in cytopenia, daily activity and well-being. "
06/01/2023 - "Splenectomy is considered an effective treatment for peripheral cytopenia in patients with HCL. "
07/01/2005 - "We assume that splenectomy is an effective treatment for resistant immune cytopenias after allo-HSCT. "
06/01/2002 - "We conclude that splenectomy is an efficient treatment for splenic MZL, but that it may be delayed until the occurrence of symptoms or cytopenia."
04/01/2000 - "Before 1980 the only effective treatment for HCL was splenectomy, which resolved the cytopenia but did not eliminate the disease from the bone marrow. "

11/01/2011 - "Even with severe BMC-associated cytopenia, aggressive combination treatment regimens are indicated, since most patients show improved marrow function after chemotherapy and long-lasting survival is possible."
04/01/2008 - "These results indicate that patients with advanced MDS who achieve and remain in remission or a second refractory cytopenia phase with chemotherapy before conditioning can achieve successful long-term remissions following a myeloablative T cell depleted allogeneic HSCT."
05/01/2006 - "These data suggest that A(1-7) may be beneficial in attenuating multilineage cytopenias following chemotherapy at a dose of 100 mug/kg per day."
01/01/2023 - "Intensive cytoreduction and chemotherapy were started and the patient's cytopenias and kidney injury have improved. "
01/01/2014 - "In addition, we have briefly discussed how these models suggest improved ways to minimize and/or treat cytopenia induced by chemotherapy. "

01/01/2022 - "We evaluated the safety and efficacy of using CD34+CD45+ hematopoietic progenitors derived from MHC homozygous iPSCs (iHPs) to treat cytopenia after myeloablative hematopoietic stem cell (HSC) transplantation in a Mauritian cynomolgus macaque (MCM) nonhuman primate (NHP) model. "
01/01/2021 - "LGL in the setting of cytopenias did not predict improved transplantation outcomes compared to those with cytopenias without presence of LGL. "
04/01/2008 - "Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders had progression or relapse of their MDS (10 failures). "
10/01/1997 - "Kinetic studies can therefore be useful, by demonstrating the mechanism of cytopenia observed after transplantation, and by facilitating the choice of appropriate treatment."
11/01/2023 - "Cytopenia: a report of haplo-cord transplantation in twin brothers caused by a novel germline GATA1 mutation and family survey."

04/01/1994 - "Post-remission cytopenias resulted in a greater than 90-day delay or prevention of planned autologous bone marrow transplantation in 13 of 17 otherwise eligible patients. "
03/01/1998 - "With it has come increased incidence of post remission cytopenias and delayed engraftment following autologous bone marrow transplantation (ABMT). "
02/01/2018 - "We report a comprehensive genetic analysis of a patient with KMT2A-rearranged DCL after allogeneic bone marrow transplantation for refractory cytopenia of childhood. "
09/01/1999 - "Patient 2 had prolonged cytopenias and underwent bone marrow transplantation (BMT). "
12/01/1997 - "Autoimmune cytopenia has also been described in patients that have undergone allogeneic or autologous bone marrow transplantation. "